PL169481B1 - Sposób wytwarzania nowych pochodnych policyklicznych guanin PL PL PL - Google Patents

Sposób wytwarzania nowych pochodnych policyklicznych guanin PL PL PL

Info

Publication number
PL169481B1
PL169481B1 PL91297299A PL29729991A PL169481B1 PL 169481 B1 PL169481 B1 PL 169481B1 PL 91297299 A PL91297299 A PL 91297299A PL 29729991 A PL29729991 A PL 29729991A PL 169481 B1 PL169481 B1 PL 169481B1
Authority
PL
Poland
Prior art keywords
formula
compounds
phenylmethyl
aryl
compound
Prior art date
Application number
PL91297299A
Other languages
English (en)
Polish (pl)
Other versions
PL297299A1 (enEXAMPLES
Inventor
Bernard R Neustadt
Neil A Lindo
Kittrick Brian A Mc
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PL297299A1 publication Critical patent/PL297299A1/xx
Publication of PL169481B1 publication Critical patent/PL169481B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Filtering Materials (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
PL91297299A 1990-06-21 1991-06-20 Sposób wytwarzania nowych pochodnych policyklicznych guanin PL PL PL PL169481B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54156890A 1990-06-21 1990-06-21
PCT/US1991/004154 WO1991019717A1 (en) 1990-06-21 1991-06-20 Polycyclic guanine derivatives

Publications (2)

Publication Number Publication Date
PL297299A1 PL297299A1 (enEXAMPLES) 1992-07-13
PL169481B1 true PL169481B1 (pl) 1996-07-31

Family

ID=24160139

Family Applications (1)

Application Number Title Priority Date Filing Date
PL91297299A PL169481B1 (pl) 1990-06-21 1991-06-20 Sposób wytwarzania nowych pochodnych policyklicznych guanin PL PL PL

Country Status (21)

Country Link
US (1) US5393755A (enEXAMPLES)
EP (1) EP0538332B1 (enEXAMPLES)
JP (1) JPH0747589B2 (enEXAMPLES)
KR (1) KR960004532B1 (enEXAMPLES)
AT (1) ATE155786T1 (enEXAMPLES)
AU (1) AU651607B2 (enEXAMPLES)
CA (1) CA2085733C (enEXAMPLES)
CZ (1) CZ281920B6 (enEXAMPLES)
DE (1) DE69126980T2 (enEXAMPLES)
FI (1) FI925731A7 (enEXAMPLES)
HU (1) HUT65623A (enEXAMPLES)
IE (1) IE912126A1 (enEXAMPLES)
IL (1) IL98559A0 (enEXAMPLES)
NO (1) NO924940D0 (enEXAMPLES)
NZ (1) NZ238609A (enEXAMPLES)
OA (1) OA09723A (enEXAMPLES)
PL (1) PL169481B1 (enEXAMPLES)
RU (1) RU2080322C1 (enEXAMPLES)
TW (1) TW197441B (enEXAMPLES)
WO (1) WO1991019717A1 (enEXAMPLES)
ZA (1) ZA914727B (enEXAMPLES)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI953981A0 (fi) * 1993-02-26 1995-08-24 Schering Corp 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
AR004752A1 (es) * 1995-11-28 1999-03-10 Schering Corp 2'-[[4'-halo-[1,1'-bifenil]-4-il]metil]-5'-metil-espiro[ciclopentano-1,7' (8'h)-[3h imidazo[2,1-b]purin]-4'(5'h)-onas, uso del mismo para la preparacionde un medicamento, composicion farmaceutica y un proceso para su preparacion.
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60226615D1 (enEXAMPLES) * 2001-08-28 2008-06-26 Schering Corp
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
WO2003042216A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
ES2270047T3 (es) * 2002-05-31 2007-04-01 Schering Corporation Proceso para preparar inhibidores de la fosfodiesterasa v de xantina y sus precursores.
ATE363483T1 (de) * 2003-07-31 2007-06-15 Schering Corp Metabolit eines xanthinphosphodiesterase-5- inhibitors und derivate davon, die sich zur behandlung von errektionsstörungen eignen
WO2005012293A1 (ja) * 2003-08-01 2005-02-10 Nippon Soda Co., Ltd. フェニルアゾール化合物、製造法および抗酸化薬
BRPI0416202A (pt) * 2003-11-21 2006-12-26 Schering Corp formulações inibidoras de fosfodiesterase v
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
JP5084725B2 (ja) * 2005-06-06 2012-11-28 武田薬品工業株式会社 有機化合物
WO2007025103A2 (en) * 2005-08-23 2007-03-01 Intra-Cellular Therapies, Inc. Organic compounds for treating reduced dopamine receptor signalling activity
EP1947092B1 (en) 2005-11-09 2015-04-15 Tosoh Corporation Method for producing nucleic acid base having perfluoroalkyl group
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP5453086B2 (ja) * 2006-06-06 2014-03-26 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
ES2411604T3 (es) 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US9006258B2 (en) * 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
MX2010000098A (es) * 2007-06-21 2010-04-21 Schering Corp Derivados de guanina policiclicos y sus metodos de uso.
CN104370918A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
WO2010065153A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
BRPI0922808A2 (pt) * 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
MA32941B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
EP2358204B1 (en) * 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
CA2740391A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
EP2405917B1 (en) 2009-03-13 2014-04-23 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2010132127A1 (en) 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
WO2011081915A2 (en) * 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
JP5911854B2 (ja) 2010-05-31 2016-04-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
WO2014127331A1 (en) 2013-02-17 2014-08-21 Intra-Cellular Therapies, Inc. Novel uses
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
WO2015196186A1 (en) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Organic compounds
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
KR102332957B1 (ko) 2014-09-17 2021-11-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 화합물 및 방법
EP3226870B1 (en) 2014-12-06 2019-09-25 Intra-Cellular Therapies, Inc. Organic compounds
WO2016090382A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1095906A (en) * 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
BE863525A (fr) * 1977-02-14 1978-07-31 Bristol Myers Co Heterocyclopyrimidines
US5064947A (en) * 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
ZA902282B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor compounds
US5173492A (en) * 1989-09-14 1992-12-22 Kyowa Hakko Kogyo Co., Ltd. s-Triazolo(3,4-I)purine derivatives
US5270316A (en) * 1989-10-20 1993-12-14 Kyowa Hakko Kogyo Co., Ltd. Condensed purine derivatives

Also Published As

Publication number Publication date
CA2085733A1 (en) 1991-12-22
TW197441B (enEXAMPLES) 1993-01-01
DE69126980T2 (de) 1998-01-08
IL98559A0 (en) 1992-07-15
ZA914727B (en) 1992-03-25
FI925731A0 (fi) 1992-12-17
DE69126980D1 (de) 1997-09-04
ATE155786T1 (de) 1997-08-15
IE912126A1 (en) 1992-01-01
EP0538332B1 (en) 1997-07-23
CZ281920B6 (cs) 1997-04-16
CA2085733C (en) 1996-03-05
FI925731A7 (fi) 1992-12-17
WO1991019717A1 (en) 1991-12-26
US5393755A (en) 1995-02-28
NO924940L (no) 1992-12-18
OA09723A (en) 1993-08-30
PL297299A1 (enEXAMPLES) 1992-07-13
KR960004532B1 (ko) 1996-04-06
JPH0747589B2 (ja) 1995-05-24
HU9204032D0 (en) 1993-03-29
EP0538332A1 (en) 1993-04-28
HUT65623A (en) 1994-07-28
AU8199291A (en) 1992-01-07
RU2080322C1 (ru) 1997-05-27
JPH05508647A (ja) 1993-12-02
NZ238609A (en) 1993-12-23
NO924940D0 (no) 1992-12-18
CZ374992A3 (en) 1993-10-13
AU651607B2 (en) 1994-07-28

Similar Documents

Publication Publication Date Title
PL169481B1 (pl) Sposób wytwarzania nowych pochodnych policyklicznych guanin PL PL PL
US6174884B1 (en) 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives
EP2769980B1 (en) Pyrazoloquinoline derivative as pde9 inhibitors
EP2142546B1 (en) Purinyl derivatives and their use as potassium channel modulators
EP3286194B1 (en) Imidazotriazinones as pde1 inhibitors
US20030176698A1 (en) Fused purine derivatives
KR20080013886A (ko) 면역억제용 퓨린 및 이미다조피리딘 유도체
CZ16796A3 (en) 2,8-disubstituted quinazolines, process of their preparation, pharmaceutical composition such compounds and their use
JP2016537366A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
KR20010032979A (ko) Ｐｄｅ ｉｖ 억제 작용을 하는 퓨린 화합물과 그의 합성방법
EP0856003A1 (en) 1,2,4-TRIAZOLO 1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES HAVING ANTAGONISTIC ACTIVITY ON ADENOSINE A 2a? RECEPTOR
BRPI0622030A2 (pt) Derivados de purina 7-substituída, para imunossupressão
EP2708540B1 (en) Pyrimido-diazepinone compound
BG61728B1 (bg) 2,9-дизаместени пурин-6-они
HU194878B (en) Process for producing imidazol derivatives condensed with nitrogen-containing ring and pharmaceutical compositions containing them
US20230167133A1 (en) 7h-pyrrolo[2,3-d]pyrimidines and preparation and uses thereof
TW202413379A (zh) 4-烷氧基吡咯并[2,1-f][1,2,4]三𠯤及其製備與用途
EP1888585B1 (en) Tetracyclic azapyrazinoindolines as 5-ht2 ligands
US11952377B2 (en) Quinolines and azaquinolines as inhibitors of CD38
US20080108652A1 (en) Imidazo (4,5-B) pyridine-derivatives as inducible no-synthase inhibitors
FI98461C (fi) Menetelmä terapeuttisesti käyttökelpoisten yhdisteiden valmistamiseksi
US20240124464A1 (en) Substituted fused bicyclic compound as kinase inhibitor and use thereof
EP0884318A1 (en) Fused purine derivatives
US6458792B1 (en) Compounds
WO2003043637A1 (en) 3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands